E-mail a Wiley Online Library Link

Robert M. Sharkey, Habibe Karacay and David M. Goldenberg Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides Cancer 116

Version of Record online: 2 FEB 2010 | DOI: 10.1002/cncr.24802

Radioimmunotherapy is a safe and effective treatment of non-Hodgkin lymphoma that combines an anti-CD20 IgG radioconjugate with a large amount of unlabeled anti-CD20 antibody intended to allow the radioimmunoconjugate to bypass the CD20 antigen sink, but in excess, it could compromise the efficacy of the radioconjugate. Other approaches, such as combining anti-CD20 antibody therapy with radioimmunoconjugate that binds to another B-cell specific antigen, can enhance responses, or in the case of pretargeting procedures with consolidation anti-CD20 antibody therapy, enhance responses with reduced toxicity.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field